View Mobile Friendly Conference List »

Setting new standards in information exchange for the pharmaceutical and biotech industry


Xeris is Looking Forward to PODD 2013

  • July 10, 2013

  • Xeris is looking forward to participating in the PODD conference again this year, especially since the  event aligns with our goal to pursue partnering opportunities as part of our XeriScreen™ program.  With our novel formulation technologies, XeriSol™ and XeriJect™, we strive to develop a number of  therapeutics and delivery technologies for ready-to-use, low-volume, subcutaneous injections of small molecules and biologics that are not stable or soluble in aqueous systems.

    Our technologies uniquely address the sources of drug degradation with our non-aqueous formulation process. The elimination of water and most excipients in the formulation and the use of non-aqueous diluents and solvents allow drugs to be pre-mixed, resulting in ultra-low volume solutions and suspensions that are ready for injection, patient-friendly, and that can be used across multiple delivery devices (e.g. auto-injectors and pumps).

    For our XeriSol™ products, we’ve found that some bio-pharmaceuticals coupled with biocompatible  solvents form highly-concentrated solutions. This has the added advantage of maintaining relatively lowvolumes while allowing the use of commercially available needles, syringes, and auto-injection devices, significantly accelerating the time to market.

    Our XeriSol™ product portfolio starts with glucagon for the treatment of hypoglycemia in the insulin-dependent diabetes population. XeriSol™ Glucagon will be applied to the G-Pen™ for severe hypoglycemic events and the G-Pen Mini™ for precise dosing and non-caloric dosing applications for mild to moderate hypoglycemia. We’re also using the same formulation for our G-Pump™ glucagon for use in the bionic pancreas, often referred to as the “Holy Grail” in diabetes care and management.

    Our XeriJect™ technology dramatically reduces or eliminates excipients for lyophilization powders. This results in protein powders that are more compact on a volume/weight basis. The powders used to create our ready to inject Micro-Pastes™ have significantly higher protein concentrations when compared to traditionally manufactured protein powders that require reconstitution with sterile water prior to injection. Our Micro-Pastes™ significantly reduce injection volume (up to 1,000 times) and eliminate the need for water-based reconstitution.

    We welcome opportunities to discuss the formulation of stable and small molecules, mAbs, proteins, and peptides that leverage our technology platform. For more information about our programs, please
    contact Doug Baum ( We look forward to meeting you at PODD 2013!